Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells
Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cellsDecitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells, Published online: 09 February 2018; doi:10.1038/s41388-018-0125-3Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells
In recent years, researchers working on forms of telomerase gene therapy have produced evidence to show that increased levels and activity of telomerase does not raise cancer risk in mice. The open access paper and publicity materials noted below report the latest example. Extra telomerase increases the sort of activities that are beneficial in the context of improved regenerative capacity, but might be thought to raise the risk of cancer when they take place in the damaged environment of old tissue. This means more stem cell activity, more cellular replication, and so forth. Somatic cells are limited in the degree ...
Authors: Yu P, Kusuma JD, Suarez MAR, Pamela Koong Shiao SY Abstract Glutathione S transferase mu 1 (GSTM1) gene has been associated with lung cancer (LC) risk, for GSTM1 enzyme playing a vital role in detoxification pathway and protective against toxic insults. The major objective of this study was to investigate GSTM1 deletion pattern and its association with LC in the world's population by using meta-prediction techniques. The secondary objective was to examine the effects of air pollution, smoking status, and other factors for gene-environment interactions with GSTM1 deletion and LC risk. We completed a compreh...
Conclusion: ctDNA monitoring can be used for early detection of non-response in patients without targetable mutations, and therefore could supplement imaging data for treatment monitoring in this subset of patients. PMID: 30123427 [PubMed]
Authors: Lin YC, Lin CH, Yeh YC, Ho HL, Wu YC, Chen MY, Chou TY Abstract Tumor cell heterogeneity can make selection of appropriate interventions to lung cancer a challenge. Novel biomarkers predictive of disease risk and treatment response are needed to improve personalized treatment strategies. O-GlcNAcylation, the attachment of β-N-acetylglucosamine (O-GlcNAc) to serine or threonine residues of intracellular proteins, modulates protein functions and is implicated in cancer pathogenesis. O-GlcNAc-transferase (OGT) and O-GlcNAcase (OGA) catalyze O-GlcNAc addition and removal, respectively. We used immunohisto...
ConclusionsThe occurrence and severity of skin rash correlated with increase in erlotinib trough concentrations only in Chinese patients with exon 19 deletion; the erlotinib trough concentrations were not associated with diarrhea.
Condition: Small Cell Lung Cancer Interventions: Drug: SC-011; Drug: ABBV-181 Sponsor: AbbVie Not yet recruiting
With the increased use of next-generation sequencing (NGS) to identify mutations in patient's own cancer cells, the off-label usage of non-approved drugs is on the rise. In this interview, Federico Ca... Author: VJOncology Added: 08/21/2018
Authors: Maier HT, Augustin F PMID: 30123563 [PubMed]
Editorial on "upfront surgery as first-line therapy in selected patients with stage IIIA non-small cell lung cancer". J Thorac Dis. 2018 Jul;10(Suppl 18):S2192-S2194 Authors: Lin H, Qiao K PMID: 30123558 [PubMed]
Authors: Chalela R, Gea J, Barreiro E PMID: 30123556 [PubMed]